{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:48:10Z","timestamp":1786978090132,"version":"build-2736575974"},"reference-count":45,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study evaluated the cost\u2010effectiveness of maribavir versus investigator\u2010assigned therapy (IAT; valganciclovir\/ganciclovir, foscarnet, or cidofovir) for post\u2010transplant refractory cytomegalovirus (CMV) infection with or without resistance. A two\u2010stage Markov model was designed using data from the SOLSTICE trial (NCT02931539), real\u2010world multinational observational studies, and published literature. Stage 1 (0\u201378 weeks) comprised clinically significant CMV (csCMV), non\u2010clinically significant CMV (n\u2010csCMV), and dead states; stage 2 (78 weeks\u2013lifetime) comprised alive and dead states. Total costs (2022 USD) and quality\u2010adjusted life years (QALYs) were estimated for the maribavir and IAT cohorts. An incremental cost\u2010effectiveness ratio was calculated to determine cost\u2010effectiveness against a willingness\u2010to\u2010pay\u00a0threshold of $100 000\/QALY. Compared with IAT, maribavir had lower costs ($139\u2009751 vs $147\u2009949) and greater QALYs (6.04 vs 5.83), making it cost\u2010saving and more cost\u2010effective. Maribavir had higher acquisition costs compared with IAT ($80\u2009531 vs $65\u2009285), but lower costs associated with administration\/monitoring ($16\u2009493 vs $27\u2009563), adverse events (AEs) ($11\u2009055 vs $16\u2009114), hospitalization ($27 157 vs $33\u2009905), and graft loss ($4516 vs $5081), thus making treatment with maribavir cost\u2010saving. Maribavir\u2010treated patients spent more time without CMV compared with IAT\u2010treated patients (0.85 years vs 0.68 years), leading to lower retreatment costs for maribavir (cost savings: \u2212$42\u2009970.80). Compared with IAT, maribavir was more cost\u2010effective for transplant recipients with refractory CMV, owing to better clinical efficacy and avoidance of high costs associated with administration, monitoring, AEs, and hospitalizations. These results can inform healthcare decision\u2010makers on the most effective use of their resources for post\u2010transplant refractory CMV treatment.<\/jats:p>","DOI":"10.1002\/jmv.29609","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T07:18:31Z","timestamp":1713770311000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost\u2010effectiveness of maribavir versus conventional antiviral therapies for post\u2010transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective"],"prefix":"10.1002","volume":"96","author":[{"given":"Bob G.","family":"Schultz","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc. Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille N.","family":"Kotton","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division Massachusetts General Hospital Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginita","family":"Jutlla","sequence":"additional","affiliation":[{"name":"Parexel Health Economics and Outcomes Research Modeling London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Ressa","sequence":"additional","affiliation":[{"name":"Parexel Health Economics and Outcomes Research Modeling London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam","family":"de Lacey","sequence":"additional","affiliation":[{"name":"Parexel Health Economics and Outcomes Research Modeling London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emtiyaz","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Parexel Health Economics and Outcomes Research Modeling London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien","family":"Bo","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Fenu","sequence":"additional","affiliation":[{"name":"Takeda Global Health Economics Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele K.","family":"Gelone","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc. Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Etienne","family":"Poirrier","sequence":"additional","affiliation":[{"name":"Parexel Health Economics and Outcomes Research Modeling Wavre Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L.","family":"Amorosi","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12686"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2018.08.004"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2015(07)09"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix259"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02897.x"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-688432"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2021.1915074"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.03.019"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy696"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2015.266"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12852"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2046388"},{"key":"e_1_2_10_15_1","unstructured":"MoranK ChengW SchultzB et al. Healthcare resource utilization and economic burden among hematopoietic cell and solid organ transplant recipients with cytomegalovirus requiring retreatment or multiple treatments in the US. Academy of Managed Care Pharmacy Nexus. 2022.28(10a)."},{"issue":"6","key":"e_1_2_10_16_1","first-page":"S1099","article-title":"A multinational study assessing treatment patterns, clinical outcomes, and healthcare resource utilization in solid organ transplant recipients with refractory\/resistant cytomegalovirus infection or intolerance to anti\u2010cytomegalovirus therapy","volume":"23","author":"Blumberg E","year":"2023","journal-title":"Am J Transplant (AJT)"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-024-02239-w"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/60.suppl_8.S9"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab988"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14064"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.1265"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.04.1289"},{"key":"e_1_2_10_23_1","unstructured":"Institute for Clinical and Economic Review.2020. A Guide to ICER's Methods for Health Technology Assessment.https:\/\/icer.org\/wp-content\/uploads\/2021\/01\/ICER_HTA_Guide_102720.pdf"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1717030"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12732"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.04.005"},{"key":"e_1_2_10_27_1","unstructured":"PapanicolaouG AveryR EinseleH et al. Multinational study of treatment practices and outcomes for allogeneic hematopoietic stem cell transplant recipients with post\u2010transplant cytomegalovirus. TCT 2023 LBA19. 2023."},{"key":"e_1_2_10_28_1","unstructured":"Agency for Healthcare Research and Quality.2022. Healthcare Cost & Utilization Project.https:\/\/hcup-us.ahrq.gov\/nisoverview.jsp"},{"key":"e_1_2_10_29_1","unstructured":"Medi\u2010Span.Price Rx.2023.https:\/\/www.wolterskluwer.com\/en\/solutions\/medi-span\/price-rx"},{"key":"e_1_2_10_30_1","unstructured":"Centers for Medicare & Medicaid Services.Clinical Laboratory Fee Schedule.2023.https:\/\/www.cms.gov\/medicare\/medicare-fee-for-service-payment\/clinicallabfeesched"},{"key":"e_1_2_10_31_1","unstructured":"Centers for Medicare & Medicaid Services.Physician Fee Schedule.2023.https:\/\/www.cms.gov\/medicare\/medicare-fee-for-service-payment\/physicianfeesched"},{"key":"e_1_2_10_32_1","unstructured":"Shoemaker\u2010HuntS McClellanS BaconO et al.Cost of Dispensing Study.2020.https:\/\/www.nacds.org\/pdfs\/pharmacy\/2020\/NACDS-NASP-NCPA-COD-Report-01-31-2020-Final.pdf"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00045.x"},{"key":"e_1_2_10_34_1","unstructured":"National Institute for Health and Care Excellence.NICE Health Technology Evaluations: The Manual (PMG36).2022.https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation#the-reference-case-framework"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00605.x"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1792"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.02.017"},{"key":"e_1_2_10_38_1","unstructured":"United States Census Bureau. Income in the United States: 2021. Accessed September 6 2023.https:\/\/www.census.gov\/library\/publications\/2022\/demo\/p60-276.html"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181ff500d"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008111166"},{"key":"e_1_2_10_41_1","unstructured":"National Institute for Health and Care Excellence.Single technology appeal: Letermovir prophylaxis for cytomegalovirus disease after allogeneic stem cell transplant.2018.https:\/\/www.nice.org.uk\/guidance\/ta591\/evidence\/appraisal-consultation-committee-papers-pdf-6846305293"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad293"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.11.038"},{"key":"e_1_2_10_45_1","doi-asserted-by":"crossref","unstructured":"ChowdhuryE deLaceyT RessaR AmorosiSL K.D. Multinational real\u2010world data in transplant patients withtransplant patients with refractory\/resistant cytomegalovirus infection enhancecytomegalovirus infection enhance cost\u2010effectiveness modeling outcomes. ISPOR Europe. 2023.","DOI":"10.1016\/j.jval.2023.09.750"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.811"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.29609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:15:56Z","timestamp":1744902956000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.29609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1002\/jmv.29609"],"URL":"https:\/\/doi.org\/10.1002\/jmv.29609","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"2023-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29609"}}